EC
DNLI icon

Euclidean Capital’s Denali Therapeutics DNLI Stock Holding History

Euclidean Capital’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-323,749
Closed -$25.4M – 12
2021
Q2 		$25.4M Hold
323,749
– – 8.24% 3
2021
Q1 		$18.5M Hold
323,749
– – 6.19% 5
2020
Q4 		$27.1M Buy
+323,749
New +$19.6M 5.74% 4

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Euclidean Capital's DNLI Position: Q3 2021 in Review

Euclidean Capital sold out of Denali Therapeutics (DNLI) in Q3 2021, closing a stake of 323,749 shares — an estimated $25.4M sold.

Euclidean Capital first reported a position in DNLI in Q4 2020 and held it in 3 quarters. The position peaked at $27.1M in Q4 2020. 214 funds tracked by Wall St. Rank hold DNLI as of Q3 2021.

  • Euclidean Capital reported no remaining Denali Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Euclidean Capital sold 323,749 Denali Therapeutics shares in Q3 2021, an estimated $25.4M.
  • Euclidean Capital first reported a position in Denali Therapeutics in Q4 2020 and held it in 3 quarters.
  • Euclidean Capital's Denali Therapeutics position peaked at $27.1M in Q4 2020.
  • 214 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2021.

Based on Euclidean Capital's 13F filing for Q3 2021, filed 15 Nov 2021.